Collegium Pharmaceutical announced that its abuse-deterrent painkiller, Xtampza ER, won full marketing approval. The drug was tentatively approved back in November 2015, but the full approval was subject to a lawsuit between Collegium and Purdue. The latter company claimed that Collegium infringed on some of its patents for abuse deterrence technology.
Read more from Reuters here.